407 related articles for article (PubMed ID: 27152635)
1. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
2. Administration costs of intravenous chemotherapy in treating peripheral T-cell lymphoma.
Kruse GB; Potashman MH; Stavrakas S; Wong BJ
J Med Econ; 2014 Jul; 17(7):446-58. PubMed ID: 24758228
[TBL] [Abstract][Full Text] [Related]
3. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
5. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
7. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
8. Health Care Resource Utilization and Costs Among Medicare Beneficiaries Newly Diagnosed With Peripheral T-cell Lymphoma: A Retrospective Claims Analysis.
Shah A; Petrilla A; Rebeira M; Feliciano J; Lisano J; LeBlanc TW
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e1-e9. PubMed ID: 33184000
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
10. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
11. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.
Burke JP; Hunsche E; Régulier E; Nagao M; Buzinec P; Drake Iii W
Am J Manag Care; 2015 Jan; 21(3 Suppl):s47-58. PubMed ID: 25734573
[TBL] [Abstract][Full Text] [Related]
12. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
[TBL] [Abstract][Full Text] [Related]
13. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.
Bonafede M; Richhariya A; Cai Q; Josephson NC; McMorrow D; Garfin PM; Perales MA
J Med Econ; 2017 Dec; 20(12):1244-1251. PubMed ID: 28782449
[TBL] [Abstract][Full Text] [Related]
14. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
15. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
16. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
17. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
19. Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventions.
Bagalman E; Muser E; Choi JC; Durden E; Macfadden W; Haskins JT; Dirani R
Clin Ther; 2011 Oct; 33(10):1381-1390.e4. PubMed ID: 22000656
[TBL] [Abstract][Full Text] [Related]
20. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
